Psoriatic Arthritis (PsA), an immune mediated inflammatory arthritis, affects a quarter of patients with cutaneous psoriasis, usually after psoriasis onset. Early diagnosis of PsA is challenging. A biomarker-based diagnostic test may facilitate early diagnosis.
Objectives
We aimed to determine whether specific clinical features or genetic and protein markers, alone or in combination, can distinguish patients with PsA from those with psoriasis without PsA (PsC).
Methods
Patients with PsA and PsC were identified from a database of patients with psoriatic disease. Detailed demographic and clinical information were collected at time of assessment. Single-nucleotide polymorphisms (SNPs) of 19 “PsA weighted” genes were genotyped. Serum samples were used to assess 15 protein markers by ELISA. Association between clinical, genetic and protein markers and PsA were determined, and models were developed to discriminate PsA from PsC using machine learning algorithms.
Results
Demographic and clinical information had low predictive value in distinguishing PsA from PsC (AUC - 0.607, P < .01). SNP and protein panels also had low value in discriminating PsA from PsC (AUC - 0.691, P < .001 and AUC - 0.694, P < .001, respectively). Combining protein, SNPs and clinical features provided better discriminatory value (best performing model: Random Forest, AUC - 0.733, P < .001).
Conclusion
Combining previously identified clinical, genetic and protein markers have a fair ability to differentiate PsA from PsC. Further studies are required for identifying better diagnostic signatures.
AlinaghiFCalovMKristensenLE, et al.Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265.e19. doi:10.1016/j.jaad.2018.06.027
3.
ChandranVRaychaudhuriSP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314-J321. doi:10.1016/j.jaut.2009.12.001
4.
GladmanDDAntoniCMeasePCleggDONashP. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14-ii17. doi:10.1136/ard.2004.032482
5.
ReichKKrugerKMossnerRAugustinM. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040-1047. doi:10.1111/j.1365-2133.2008.09023.x
6.
HaroonMGPFitzGeraldO. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045-1050.
7.
ChandranVSchentagCTGladmanDD. Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. J Rheumatol. 2008;35(10):2069-2070.
8.
D'AngeloSMennilloGACutroMS, et al.Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. J Rheumatol. 2009;36(2):368-370. doi:10.3899/jrheum.080596
9.
RidaMAChandranV. Challenges in the clinical diagnosis of psoriatic arthritis. Clin Immunol. 2020;214:108390. doi:10.1016/j.clim.2020.108390
10.
SoomroMHumRBartonABowesJ. Genetic studies investigating susceptibility to psoriatic arthritis: a narrative review. Clin Ther. 2023;45(9):810-815. doi:10.1016/j.clinthera.2023.07.003
11.
StuartPENairRPEllinghausE, et al.Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet. 2010;42(11):1000-1004. doi:10.1038/ng.693
12.
StuartPENairRPTsoiLC, et al.Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet. 2015;97(6):816-836. doi:10.1016/j.ajhg.2015.10.019
13.
AbjiFPollockRALiangKChandranVGladmanDD. Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis Rheumatol. 2016;68(12):2911-2916. doi:10.1002/art.39800
14.
ChandranV. Soluble biomarkers may differentiate psoriasis from psoriatic arthritis. J Rheumatol Suppl. 2012;89:65-66. doi:10.3899/jrheum.120247
15.
ChandranVAbjiFPerruccioAV, et al.Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis. Ann Rheum Dis. 2019;78(6):796-801. doi:10.1136/annrheumdis-2018-214737
16.
CretuDGaoLLiangKSoosaipillaiADiamandisEPChandranV. Differentiating psoriatic arthritis from psoriasis without psoriatic arthritis using novel serum biomarkers. Arthritis Care Res. 2018;70(3):454-461. doi:10.1002/acr.23298
17.
CretuDLiangKSaraonPBatruchIDiamandisEPChandranV. Quantitative tandem mass-spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers. Clin Proteomics. 2015;12(1):1. doi:10.1186/1559-0275-12-1
18.
CretuDPrassasISaraonP, et al.Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. Clin Proteomics. 2014;11(1):27. doi:10.1186/1559-0275-11-27
19.
Geneva-PopovaMPopova-BelovaSPopovaVChompalovKBatalovA. Assessment of serum and synovial fluid MMP-3 and MPO as biomarkers for psoriatic arthritis and their relation to disease activity indices. Rheumatol Int. 2022;42(9):1605-1615. doi:10.1007/s00296-022-05159-4
20.
Holm NielsenSMageeCGroenSS, et al.Differentiating patients with psoriasis from psoriatic arthritis using collagen biomarkers. Clin Exp Rheumatol. 2023;41(3):574-580. doi:10.55563/clinexprheumatol/jmt9jv
21.
LiuJKumarSHongJ, et al.Combined single cell transcriptome and surface epitope profiling identifies potential biomarkers of psoriatic arthritis and facilitates diagnosis via machine learning. Front Immunol. 2022;13:835760. doi:10.3389/fimmu.2022.835760
22.
MulderMLMHeXvan den ReekJ, et al.Blood-based immune profiling combined with machine learning discriminates psoriatic arthritis from psoriasis patients. Int J Mol Sci. 2021;22(20):10990. doi:10.3390/ijms222010990
23.
ShapiroJGetzBCohenSB, et al.Evaluation of a machine learning tool for the early identification of patients with undiagnosed psoriatic arthritis - a retrospective population-based study. J Transl Autoimmun. 2023;7:100207. doi:10.1016/j.jtauto.2023.100207
24.
LeeLTYangHCNguyenPAMuhtarMSLiYJ. Machine learning approaches for predicting psoriatic arthritis risk using electronic medical records: population-based study. J Med Internet Res. 2023;25:e39972. doi:10.2196/39972
25.
TaylorWGladmanDHelliwellP, et al.Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-2673. doi:10.1002/art.21972
26.
KentWJSugnetCWFureyTS, et al.The human genome browser at UCSC. Genome Res. 2002;12(6):996-1006. doi:10.1101/gr.229102
27.
Bernd BischlMLKotthoffLSchiffnerJ, et al.mlr: machine learning in R. J Mach Learn Res. 2016;17(170):1-5.
28.
RobinXTurckNHainardA, et al.pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinf. 2011;12:77. doi:10.1186/1471-2105-12-77
FurerVWollmanJLevartovskyD, et al.Sex-based differences in sonographic and clinical findings among patients with psoriatic arthritis. J Rheumatol. 2023;50(2):197-203. doi:10.3899/jrheum.220547
31.
QueiroRSeoane-MatoDLaizA, et al.Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis. Clin Exp Rheumatol. 2023;41(1):137-144. doi:10.55563/clinexprheumatol/077ul6
32.
TarannumSLeungYYJohnsonSR, et al.Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022;18(9):513-526. doi:10.1038/s41584-022-00810-7
33.
MerolaJFTianHPatilD, et al.Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: retrospective analysis of an electronic health records database in the United States. J Am Acad Dermatol. 2022;86(4):748-757. doi:10.1016/j.jaad.2021.09.019
34.
PatrickMTStuartPERajaK, et al.Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nat Commun. 2018;9(1):4178. doi:10.1038/s41467-018-06672-6
35.
SoomroMStadlerMDandN, et al.Comparative genetic analysis of psoriatic arthritis and psoriasis for the discovery of genetic risk factors and risk prediction modeling. Arthritis Rheumatol. 2022;74(9):1535-1543. doi:10.1002/art.42154
36.
WrightHLMcCarthyHSMiddletonJMarshallMJ. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med. 2009;2(1):56-64. doi:10.1007/s12178-009-9046-7
37.
ChandranVCookRJEdwinJ, et al.Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology. 2010;49(7):1399-1405. doi:10.1093/rheumatology/keq105
38.
RitchlinCTHaas-SmithSALiPHicksDGSchwarzEM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Investig. 2003;111(6):821-831. doi:10.1172/JCI16069
39.
GiachelliCMSteitzS. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 2000;19(7):615-622. doi:10.1016/s0945-053x(00)00108-6
40.
RaimondoALemboSDi CaprioR, et al.Psoriatic cutaneous inflammation promotes human monocyte differentiation into active osteoclasts, facilitating bone damage. Eur J Immunol. 2017;47(6):1062-1074. doi:10.1002/eji.201646774
41.
Przepiorka-KosinskaJMBartosinskaJRaczkiewiczD, et al.Serum concentration of osteopontin and interleukin 17 in psoriatic patients. Adv Clin Exp Med. 2020;29(2):203-208. doi:10.17219/acem/112604
42.
AminTEElFarNNGhalyNRHekalMMHassanAMElsaadanyHM. Serum level of receptor activator of nuclear factor kappa-B ligand in patients with psoriasis. Int J Dermatol. 2016;55(5):e227-e233. doi:10.1111/ijd.13159
43.
CasoFPostiglioneLCovelliB, et al.Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset sine psoriasis. Clin Rheumatol. 2019;38(9):2547-2552. doi:10.1007/s10067-019-04619-w
44.
CheleschiSTentiSBedogniGFioravantiA. Circulating Mir-140 and leptin improve the accuracy of the differential diagnosis between psoriatic arthritis and rheumatoid arthritis: a case-control study. Transl Res. 2022;239:18-34. doi:10.1016/j.trsl.2021.08.001
45.
EderLJayakarJPollockR, et al.Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis. 2013;72(12):1956-1961. doi:10.1136/annrheumdis-2012-202325
46.
Sluczanowska-GlabowskaSStaniszewskaMMarchlewiczM, et al.Adiponectin, leptin and resistin in patients with psoriasis. J Clin Med. 2023;12(2):663. doi:10.3390/jcm12020663
47.
DianiMPeregoSSansoniV, et al.Differences in osteoimmunological biomarkers predictive of psoriatic arthritis among a large Italian cohort of psoriatic patients. Int J Mol Sci. 2019;20(22):5617. doi:10.3390/ijms20225617
48.
PruensterMVoglTRothJSperandioM. S100A8/A9: from basic science to clinical application. Pharmacol Ther. 2016;167:120-131. doi:10.1016/j.pharmthera.2016.07.015
49.
AochiSTsujiKSakaguchiM, et al.Markedly elevated serum levels of calcium-binding S100A8/A9 proteins in psoriatic arthritis are due to activated monocytes/macrophages. J Am Acad Dermatol. 2011;64(5):879-887. doi:10.1016/j.jaad.2010.02.049
50.
BenoitSToksoyAAhlmannM, et al.Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Br J Dermatol. 2006;155(1):62-66. doi:10.1111/j.1365-2133.2006.07198.x
51.
LiBLiGSongZZhangZ. Serum calprotectin as a promising inflammatory biomarker in psoriatic arthritis: a 1-year longitudinal study. Rheumatol Ther. 2023;10(1):149-160. doi:10.1007/s40744-022-00501-5
52.
HuSHuangJWangW. ITGB5 as a potential diagnostic biomarker for osteoarthritis. J Musculoskelet Neuronal Interact. 2025;25(1):86-100. doi:10.22540/JMNI-25-086
53.
Mc ArdleAKwasnikASzentpeteryA, et al.Identification and evaluation of serum protein biomarkers that differentiate psoriatic arthritis from rheumatoid arthritis. Arthritis Rheumatol. 2022;74(1):81-91. doi:10.1002/art.41899
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
